Review: Optimal use of biologics in the management of Crohn’s disease

M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

W1244 Efficacy of a Third Anti-TNF Monoclonal Antibody in Crohn's Disease After Failure of Two Other Anti-TNF

(2008) Nicolas Mozziconacci et al.   GASTROENTEROLOGY

494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study

(2008) Severine Vermeire et al.   GASTROENTEROLOGY

920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial

(2008) Remo Panaccione et al.   GASTROENTEROLOGY

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET